Laurence Marton
CIK: 0001862192
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Oct 1, 2026RNXT
RenovoRx, Inc.
Award(A)DirectStock Options (right to buy)
55.9K shares- - May 22, 2026No ticker
Matternet, Inc.
Award(A)Direct52K shares- - Mar 20, 2026RNXT
RenovoRx, Inc.
Purchase(P)Indirect9.7K shares- - Oct 1, 2025RNXT
RenovoRx, Inc.
Award(A)DirectStock Options (right to buy)
47.6K shares- - May 2, 2025RNXT
RenovoRx, Inc.
Exercise(M)Direct20.5K shares at avg. $0.15$3K - Apr 8, 2025RNXT
RenovoRx, Inc.
Purchase(P)Direct12.1K shares at avg. $0.85$10K - Oct 1, 2024RNXT
RenovoRx, Inc.
Award(A)DirectStock Options (right to buy)
25.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 | RNXT RenovoRx, Inc. | Award(A) Stock Options (right to buy) | 55,924 | - | - | Direct |
| May 22, 2026 | No ticker Matternet, Inc. | Award(A) | 52,003 | - | $0 | Direct |
| Mar 20, 2026 | RNXT RenovoRx, Inc. | Purchase(P) | 9,720 | - | $0 | Indirect |
| Oct 1, 2025 | RNXT RenovoRx, Inc. | Award(A) Stock Options (right to buy) | 47,640 | - | - | Direct |
| May 2, 2025 | RNXT RenovoRx, Inc. | Exercise(M) | 20,480 | $0.15 | $3,072 | Direct |
| Apr 8, 2025 | RNXT RenovoRx, Inc. | Purchase(P) | 12,050 | $0.85 | $10,218 | Direct |
| Oct 1, 2024 | RNXT RenovoRx, Inc. | Award(A) Stock Options (right to buy) | 25,099 | - | - | Direct |
1-7 of 7 transactions
About Marton Laurence
Marton Laurence (SEC CIK 0001862192) files insider reports with the SEC as Director of RenovoRx, Inc. (RNXT) and Director of Matternet, Inc.
Signal8 holds 8 ownership filings by Marton Laurence (1 Form 3, 7 Form 4), filed between Oct 2, 2024 and Oct 2, 2026. Those filings report 7 transactions, from Oct 1, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Marton Laurence's filings is in MOUNTAIN VIEW, CA.
Recent filings by Marton Laurence
- Oct 1, 2026: Grant or award of RNXT derivative securities (Form 4, code A).
- May 22, 2026: Grant or award of Matternet, Inc. shares (Form 4, code A).
- Mar 20, 2026: Open-market purchase of RNXT shares (Form 4, code P).
- Oct 1, 2025: Grant or award of RNXT derivative securities (Form 4, code A).
- May 2, 2025: Option exercise of RNXT shares (Form 4, code M).
Other insiders filing for RenovoRx, Inc. (RNXT)
- Macfarlane K. Angela, Director
- Spiegel Robert J., Director
- RYAN UNA S, Director
- VOLL MARK, Chief Financial Officer
- Bagai Shaun, Chief Executive Officer
- Gentry Leesa, Chief Clinical Officer